The estimated Net Worth of Timothy L. Moore is at least $5.49 Million dollars as of 5 September 2021. Mr. Moore owns over 4,296 units of Cerus stock worth over $91,469 and over the last 8 years he sold CERS stock worth over $5,355,199. In addition, he makes $48,000 as Independent Director at Cerus.
Sign up
Mr. Moore CERS stock SEC Form 4 insiders trading
Timothy has made over 12 trades of the Cerus stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,296 units of CERS stock worth $8,807 on 5 September 2021.
The largest trade he's ever made was exercising 13,228 units of Cerus stock on 1 June 2021 worth over $27,117. On average, Timothy trades about 3,201 units every 56 days since 2016. As of 5 September 2021 he still owns at least 44,619 units of Cerus stock.
You can see the complete history of Mr. Moore stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Moore biography
Timothy L. Moore serves as Independent Director of the Company. Since October 2019, Mr. Moore has served as the President and Chief Technology Officer at PACT Pharma, Inc. Prior to PACT, Mr. Moore served as Executive Vice President, Technical Operations of Kite Pharma, a Gilead Company since March 2016. Prior to Kite, he spent more than 12 years at Genentech, a Roche Company, most recently as Senior Vice President, Head of Global Technical Operations – Biologics and a member of the Genentech Executive Committee. While at Genentech, he oversaw global leadership for more than 7,500 professionals across 10 internal sites and managed more than 30 contract manufacturing organizations, including end to end quality supply performance of more than 20 biological products. Mr. Moore is a former member of the board of directors FosunKite, a joint venture between Gilead Sciences, Inc. and Fosun Pharmaceuticals Inc. He holds a Bachelor of Science, Chemical Engineering from Tulsa University and an M.S. from Northwestern University.
What is the salary of Timothy Moore?
As the Independent Director of Cerus, the total compensation of Timothy Moore at Cerus is $48,000. There are 13 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
How old is Timothy Moore?
Timothy Moore is 58, he's been the Independent Director of Cerus since 2018. There are 8 older and 5 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
What's Timothy Moore's mailing address?
Timothy's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash, and Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Mr. Moore stock trades at Biolife Solutions Inc, Cerus, and Allogene Therapeutics Inc
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director